< Back to latest news & events

News

Update on G1/22 and G2/22

April 2022

In our previous article we discussed the referral to the Enlarged Board of Appeal regarding questions on entitlement to priority (G1/22 and G2/22).

The EPO has now implemented a stay on any proceedings which are dependent on the outcome of the questions posed to the Enlarged Board of Appeal.

The stay concerns examination and opposition proceedings where the entitlement to claim priority as successor in title under Article 87(1) EPC is relevant for the division’s decision and there is no evidence (beyond a possible PCT request) that the priority right was transferred from the applicant of the priority application to the applicant of the application in question before the filing date of the latter.

If proceedings are stayed, the examining or opposition division will inform the parties accordingly. In addition, there will be no communications setting time limits to reply , or any further communication until the Enlarged Board of Appeal has issued its decision. Once a decision has been made, parties will be notified regarding resumption of the proceedings.


This update was prepared by HGF Professional Standards Officer Dr Edward Pullicino.

Latest updates

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

T 1847/22: Procedural considerations in appeal: Re-ordering of requests and the impact on admissibility

Background This case concerned EP 3 085 344 B1, which relates to a wound pad, a self-adhesive member comprising a wound pad. The patent was opposed by two opponents. During …

Read article

Regulation of NGT plants in Europe- Polish Presidency proposes an alternative solution to the Patent ban

In the latest development on the new proposed legislation for the regulation of NGT (gene-edited) plants in the EU, the Polish Presidency have proposed an amendment which removes the proposed …

Read article

T 0295/22: EPO Technical Board of Appeal relies on “bonus effect” case law to find Amgen’s patent to orally administered apremilast lacking in inventive step

This case concerned Amgen’s European patent no. 2962690 for apremilast, a drug sold under the brand name Otezla®, licensed for the treatment of e.g., psoriasis and psoriatic arthritis.  The patent …

Read article
Event - 18th March 2025

Salzburg Seminar: Pitfalls in trade mark practice - What can be protected as a trade mark?

The registration of trade marks is a central component of trade mark protection – but which signs can actually be protected? In recent years, the national trade mark offices and …

Event details

Can the Chancellor’s so-called “Europe’s Silicon Valley” really replicate the innovative activity of its namesake?

The Chancellor of the UK, Rachel Reeves, recently unveiled plans to deliver an Oxford-Cambridge growth corridor that promises to boost the UK economy by up to £78 billion by 2035.  …

Read article

UPC’s CFI (Milan) extends deadline to file defence to infringement claim to align with parallel EPO appeal proceedings

Dainese S.p.A. v. Alpinestars S.p.A. & ors. UPC_CFI_472/2024 – Milan Local Division (Perrotti, Zana, Klein, Ashley) – 15 January 2025 The Milan Local Division granted a defendant’s request for an …

Read article